Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Pancreatic Neoplasms 5Leukemia, Myeloid, Acute 5Neoplasms 3Recurrence 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Colorectal Neoplasms 2Carcinoma, Merkel Cell 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pharmacokinetics 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Head and Neck Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Triple Negative Breast Cancer 1

Interventions

Ipilimumab 98pembrolizumab 84Nivolumab 82aldesleukin 51Cyclophosphamide 49Interleukin-2 38fludarabine phosphate 31Vemurafenib 31Dacarbazine 31dabrafenib 29trametinib 28Temozolomide 26fludarabine 25CTLA-4 Antigen 18Bevacizumab 18Radiosurgery 15Paclitaxel 15Carboplatin 14encorafenib 13binimetinib 13Introns 13talimogene laherparepvec 12Radiotherapy 12Interferon alpha-2 12spartalizumab 11cobimetinib 10atezolizumab 10sargramostim 9peginterferon alfa-2b 9montanide ISA 51 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Melanoma × ALT-803 × Clear all
NCT01946789 2025-01-22

A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors

Altor BioScience

Phase 1 Completed
26 enrolled 22 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡